Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2025-12-24 @ 11:44 PM
NCT ID:
NCT00126451
Eligibility Criteria:
Inclusion Criteria:
* Patient must be 18 years or older with confirmed diagnosis of breast adenocarcinoma, colorectal carcinoma or non-small cell lung cancer
* Patients must have relapsed or refractory disease following at least one chemotherapeutic treatment regimen.
* Has a measurable, positron emission tomography (PET) assessable lesion
* Adequate blood, liver, bone marrow and kidney functions
* Has not received any chemotherapy for at least 4 weeks prior to entry in this study
* Agrees to take adequate measures to prevent pregnancy.
Exclusion Criteria:
* Patient has had prior treatment with histone deacetylase (HDAC) inhibitor.
* Patient has had treatment with investigational agents within the last 30 days.
* Patient has active infection or had intravenous (IV) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs.
* Patient has HIV, hepatitis B or hepatitis C infection.
* Patient is pregnant or lactating.
* Patient has allergy to any component of the study drug.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00126451
Study Brief:
Protocol Section:
NCT00126451